201 related articles for article (PubMed ID: 34171451)
21. Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015.
Pithadia KJ; Advani PG; Citrin DE; Bekelman JE; Withrow DR; Berrington de Gonzalez A; Morton LM; Schonfeld SJ
JAMA Oncol; 2023 Aug; 9(8):1119-1123. PubMed ID: 37289449
[TBL] [Abstract][Full Text] [Related]
22. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic Body Radiation Therapy, Intensity-Modulated Radiation Therapy, and Brachytherapy Boost Modalities in Invasive Cervical Cancer: A Study of the National Cancer Data Base.
OʼDonnell B; Shiao JC; Pezzi TA; Waheed N; Sharma S; Bonnen MD; Ludwig MS
Int J Gynecol Cancer; 2018 Mar; 28(3):563-574. PubMed ID: 29324547
[TBL] [Abstract][Full Text] [Related]
24. Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.
Sood S; Ju AW; Wang H; Lei S; Uhm S; Zhang G; Suy S; Carroll J; Lynch J; Dritschilo A; Collins SP
Radiat Oncol; 2013 Aug; 8():197. PubMed ID: 23937800
[TBL] [Abstract][Full Text] [Related]
25. The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.
Jacobs BL; Yabes JG; Lopa SH; Heron DE; Chang CH; Schroeck FR; Bekelman JE; Kahn JM; Nelson JB; Barnato AE
Cancer; 2017 Aug; 123(15):2945-2954. PubMed ID: 28301689
[TBL] [Abstract][Full Text] [Related]
26. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
Lee SH; Kim HJ; Kim WC
Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer.
Tsubokura T; Yamazaki H; Masui K; Sasaki N; Shimizu D; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Nishikawa T; Okabe H
Sci Rep; 2018 Jul; 8(1):10538. PubMed ID: 30002393
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.
Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS
Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277
[TBL] [Abstract][Full Text] [Related]
30. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
Forsythe K; Blacksburg S; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
[TBL] [Abstract][Full Text] [Related]
31. Influence of Geography on Prostate Cancer Treatment.
Tang C; Lei X; Smith GL; Pan HY; Hoffman KE; Kumar R; Chapin BF; Shih YT; Frank SJ; Smith BD
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1286-1295. PubMed ID: 33316361
[TBL] [Abstract][Full Text] [Related]
32. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
[TBL] [Abstract][Full Text] [Related]
33. Cost-Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer.
Alyamani N; Song J; van Katwyk S; Thavorn K; Renaud J; Haddad A; MacPherson M; Gaudet M
Curr Oncol; 2021 Jun; 28(4):2385-2398. PubMed ID: 34202403
[TBL] [Abstract][Full Text] [Related]
34. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
[TBL] [Abstract][Full Text] [Related]
35. Second malignancy (SM) in prostate cancer patients treated with SBRT and other contemporary radiation techniques.
Blanchard P; Zelefsky MJ; Bossi A; Chargari C; Cosset JM
Radiother Oncol; 2021 Nov; 164():251-252. PubMed ID: 34627937
[No Abstract] [Full Text] [Related]
36. Pattern of Radiotherapy Treatment in Low-Risk, Intermediate-Risk, and High-Risk Prostate Cancer Patients: Analysis of National Cancer Database.
Agrawal R; Dey A; Datta S; Nassar A; Grubb W; Traughber B; Biswas T; Ove R; Podder T
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428595
[TBL] [Abstract][Full Text] [Related]
37. [Stereotactic body radiation therapy versus conventional intensity-modulated radiation therapy for the treatment of prostate cancer].
Gao QN
Zhonghua Nan Ke Xue; 2019 May; 25(5):424-429. PubMed ID: 32216228
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
[TBL] [Abstract][Full Text] [Related]
39. Evolution of advanced technologies in prostate cancer radiotherapy.
Zaorsky NG; Harrison AS; Trabulsi EJ; Gomella LG; Showalter TN; Hurwitz MD; Dicker AP; Den RB
Nat Rev Urol; 2013 Oct; 10(10):565-79. PubMed ID: 24018567
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer.
Patel SA; Switchenko JM; Fischer-Valuck B; Zhang C; Rose BS; Chen RC; Jani AB; Royce TJ
Radiat Oncol; 2020 Sep; 15(1):217. PubMed ID: 32933541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
